Cetuximab and Dabrafenib Plus Trametinib for Untreated Colonic Metastasis of BRAFV600E Mutant Primary Lung Adenocarcinoma with Signet Ring Cell Features: An Interesting and Rare Case Report

• DOI: 10.2147/ott.s375436
• Publication Date: 2022-09-26T07:20:10Z
• Authors: Shujun Jiang; Yanran Wu; Wenjie Wei; Zi Wang; Qi Wang
• Keywords: Trametinib

Colonic metastases of lung adenocarcinoma are extremely rare. Signet ring cell (SRCA) has not been described in patients with gastrointestinal metastasis adenocarcinoma. SRCA is a unique subtype strong invasion and poor prognosis, most found the due to metastases. This report describes rare case colonic from primary SRCA. A 64-year-old female was admitted Sun Yat-sen University Cancer Center for feeling nausea malaise. Following positron emission tomography CT (PET-CT) scan, widespread tumor cells were bilateral lung, liver, bone, multiple lymph nodes, but there no evidence colon. Two months later, patient received liver biopsy at Tongji Hospital Wuhan. Pathology revealed poorly differentiated conformation, immunohistochemical staining did identify original source cells. Considering that mainly derives tract serum markers elevated, we performed endoscopy on patient. The results showed an isolated polyp colon, pathology indicated considered originate based staining. Meanwhile, genetic tests identified BRAF V600E mutation. final diagnosis BRAFV 600E mutated positive expression EGFR this case, cetuximab innovatively added first-line treatment regime (dabrafenib trametinib). To date, thirty-two weeks treatment. Interestingly, tumors shrank blood normalized. Our findings offer valuable diagnostic therapeutic information BRAFV600E mutant signet features.